{"filing":{"accession_number":"0001104659-26-097949","cik":"0001512762","ticker":"CHRS","company_name":"Coherus Oncology, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"chrs-20260817x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926097949/chrs-20260817x8k.htm"},"events":[{"id":28341,"run_id":25914,"accession_number":"0001104659-26-097949","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Coherus Oncology entered into a Loan and Security Agreement on August 12, 2026, creating a new senior secured term loan facility of $55 million (Tranche A) with maturity in August 2031. The company drew the full amount on August 14, 2026, using proceeds to repay prior debt and fund working capital, with improved terms (4.15% + greater of Prime/6.75%) compared to the prior facility.","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30257,"accession_number":"0001104659-26-097949","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Coherus Oncology entered into a Loan and Security Agreement on August 12, 2026, creating a new senior secured term loan facility of $55 million (Tranche A) with maturity in August 2031. The company drew the full amount on August 14, 2026, using proceeds to repay prior debt and fund working capital. This is a material creation of a direct financial obligation under Item 1.01, distinct from a covenant breach or refinancing of existing debt alone—the new facility extends maturity beyond anticipated product launches and provides incremental capital with improved terms (4.15% + greater of Prime/6.75% versus prior 8.0% + SOFR).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:26.353690+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30259,"accession_number":"0001104659-26-097949","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 explicitly addresses creation of a direct financial obligation. The filing incorporates disclosure from Item 1.01 (a business combination or material agreement), indicating a debt or financing arrangement. Without access to the Item 1.01 details, debt_issuance is the most probable classification for a direct financial obligation disclosure, though the specific nature depends on what Item 1.01 describes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:26.353690+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":28342,"run_id":25914,"accession_number":"0001104659-26-097949","anchor_item_number":"1.02","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Coherus Oncology terminated its Prior Loan Agreement on August 14, 2026, following full repayment of outstanding amounts and release of all security interests, as part of refinancing into the new senior secured term loan facility.","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30258,"accession_number":"0001104659-26-097949","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of a material loan agreement (the \"Prior Loan Agreement\") following full repayment of outstanding amounts on August 14, 2026, with release of all security interests. While this is a debt-related event, it represents the elimination of an existing financial obligation rather than creation of new debt (debt_issuance) or breach of covenant terms (covenant_breach). The termination of a material definitive agreement affecting the company's capital structure is material to investors, but the specific event type—debt payoff and agreement termination—fits best under financial_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:26.353690+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30257,"accession_number":"0001104659-26-097949","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Coherus Oncology entered into a Loan and Security Agreement on August 12, 2026, creating a new senior secured term loan facility of $55 million (Tranche A) with maturity in August 2031. The company drew the full amount on August 14, 2026, using proceeds to repay prior debt and fund working capital. This is a material creation of a direct financial obligation under Item 1.01, distinct from a covenant breach or refinancing of existing debt alone—the new facility extends maturity beyond anticipated product launches and provides incremental capital with improved terms (4.15% + greater of Prime/6.75% versus prior 8.0% + SOFR).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:26.353690+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17"},{"id":30258,"accession_number":"0001104659-26-097949","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of a material loan agreement (the \"Prior Loan Agreement\") following full repayment of outstanding amounts on August 14, 2026, with release of all security interests. While this is a debt-related event, it represents the elimination of an existing financial obligation rather than creation of new debt (debt_issuance) or breach of covenant terms (covenant_breach). The termination of a material definitive agreement affecting the company's capital structure is material to investors, but the specific event type—debt payoff and agreement termination—fits best under financial_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:26.353690+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17"},{"id":30259,"accession_number":"0001104659-26-097949","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 explicitly addresses creation of a direct financial obligation. The filing incorporates disclosure from Item 1.01 (a business combination or material agreement), indicating a debt or financing arrangement. Without access to the Item 1.01 details, debt_issuance is the most probable classification for a direct financial obligation disclosure, though the specific nature depends on what Item 1.01 describes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-18T00:05:26.353690+00:00","company_name":"Coherus Oncology, Inc.","ticker":"CHRS","filing_date":"2026-08-17"}]}